Clinical Scorecard: DOACs may benefit patients at intermediate risk of AF
At a Glance
| Category | Detail |
|---|---|
| Condition | Atrial Fibrillation |
| Key Mechanisms | Direct oral anticoagulants (DOACs) may reduce composite clinical events compared to no anticoagulation. |
| Target Population | Patients with atrial fibrillation at intermediate stroke risk (CHA₂DS₂-VASc score of 1 in men or 2 in women). |
| Care Setting | Multicenter, open-label, randomized trial. |
Key Highlights
- 1,803 patients enrolled across 18 centers in South Korea.
- Primary outcome: composite of stroke, systemic embolism, major bleeding, or cardiovascular mortality at 24 months.
- 4 primary outcome events in DOAC group vs. 13 in no anticoagulation group.
- Stroke occurred in 3 patients receiving DOACs vs. 10 in no anticoagulation.
- Subgroup analyses were not adjusted for multiple comparisons.
Guideline-Based Recommendations
Diagnosis
- Atrial fibrillation diagnosis based on clinical criteria.
Management
- Consider DOACs for patients with intermediate stroke risk.
Monitoring & Follow-up
- Monitor for bleeding and thromboembolic events.
Risks
- Potential for major bleeding and other adverse events.
Patient & Prescribing Data
Patients aged 19 years or older with atrial fibrillation and intermediate stroke risk.
DOACs may be associated with fewer adverse events compared to no anticoagulation.
Clinical Best Practices
- Assess CHA₂DS₂-VASc score for stroke risk.
- Consider individual patient factors when prescribing anticoagulation.
- Ensure informed consent regarding risks and benefits of DOACs.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
